ArticleThe Journal of investigative dermatology2014
Blocking von Willebrand factor for treatment of cutaneous inflammation.
Article in The Journal of investigative dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Interaction of von Willebrand factor with blood cells in flow models: a systematic review.Blood advances · 2022Pooled it
- Revealing the acute asthma ignorome: characterization and validation of uninvestigated gene networks.Scientific reports · 2016Pooled it
- Seventh Åland Island Meeting on von Willebrand Disease.Haemophilia : the official journal of the World Federation of Hemophilia · 2026Article
- Mouse models to study von Willebrand factor in inflammation: a scoping review.Intensive care medicine experimental · 2026Review
- Advancing Biomaterials Evaluation: A Human Quadruple Bone Cell Culture Reveals Molybdenum-Driven Pro-Osteogenic and Anti-osteoclastogenic Responses.ACS applied materials & interfaces · 2026Article
- Structure and multiple functions of von Willebrand factor.Haematologica · 2026Review
- von Willebrand Factor Deficiency Inhibits Endothelial-to-Mesenchymal Transition to Attenuate Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2025Article
- Sodium butyrate targets VWF to inhibit cigarette smoke extract-induced endothelial cell-macrophage crosstalk in regulating inflammatory response.Respiratory research · 2025Article
- Interplay between circulating von Willebrand factor and neutrophils: implications for inflammation, neutrophil function, and von Willebrand factor clearance.Haematologica · 2025Article
- Novel functions for von Willebrand factor.Blood · 2024Review
- Regulation of von Willebrand factor by ADAMTS13 ameliorates lipopolysaccharide-induced lung injury in mice.International journal of hematology · 2023Article
- Foreign Body Reaction (Immune Response) for Artificial Implants Can Be Avoided: An Example of Polyurethane in Mice for 1 Week.Journal of functional biomaterials · 2023Article
- Cadmium, von Willebrand factor and vascular aging.npj aging · 2023Review
- Peripheral Blood Gene Expression Profile of Infants with Atopic Dermatitis.JID innovations : skin science from molecules to population health · 2023Article
- von Willebrand factor links primary hemostasis to innate immunity.Nature communications · 2022Article
- 3D-printed lightweight dorsal skin fold chambers from PEEK reduce chamber-related animal distress.Scientific reports · 2022Article
- Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD.Blood advances · 2022Article
- The von Willebrand factor - ADAMTS-13 axis in malaria.Research and practice in thrombosis and haemostasis · 2022Article
- Role of von Willebrand factor in venous thromboembolic disease.JVS-vascular science · 2022Review
- Von Willebrand factor exerts hepatoprotective effects in acute but not chronic cholestatic liver injury in mice.Toxicology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Von Willebrand factor (VWF), a key player in hemostasis, is increasingly recognized as a proinflammatory protein. Here, we found a massive accumulation of VWF in skin biopsies of patients suffering from immune complex (IC)-mediated vasculitis (ICV). To clarify the impact of VWF on cutaneous inflammation, we induced experimental ICV either in mice treated with VWF-blocking antibodies or in VWF(-/-) mice. Interference with VWF led to a significant inhibition of the cutaneous inflammatory response. We confirmed the major findings in irritative contact dermatitis, a second model of cutaneous inflammation. In vivo imaging of cutaneous inflammation in the dorsal skinfold chamber revealed unaffected leukocyte rolling on anti-VWF treatment. However, we identified that reduced leukocyte recruitment is accompanied by reduced vascular permeability. Although VWF-mediated neutrophil recruitment to the peritoneum was described to require the VWF receptor on platelets (glycoprotein Ibα (GPIbα)), the VWF/GPIbα axis was dispensable for cutaneous inflammation. As assessed in tail bleeding assays, we could exclude interference of VWF blockade with hemostasis. Of particular importance, anti-VWF treatment was effective both in prophylactic and therapeutic administration. Thus, VWF represents a promising target for the treatment of cutaneous inflammation, e.g., leukocytoclastic vasculitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.